Overview of Glimepiride Tablets:
INSUGLO Tablets contain Glimepiride which has potency with long duration of action. Glimepiride is associated with faster glycemic control, lower total and LDL cholesterol levels and reduced short-term healthcare costs.
Glimepiride that belong to a class of benzene sulfonamides. It is first 3rd generation sulphonylurea.
INSUGLO Tablets can be used in the treatment of Type II Diabetes Mellitus
- The recommended starting dose is INSUGLO 1 mg or INSUGLO 2 mg once daily, administered with breakfast .
- After reaching a daily dose of INSUGLO 2 mg, further dose increases can be made in increments of 1 mg or 2 mg based upon the patient’s glycemic response.
- The maximum recommended dose is 8 mg once daily.
Lowering blood glucose appears to be dependent on stimulating the release of insulin from functioning pancreatic beta cells, and increasing sensitivity of peripheral tissues to insulin. Glimepiride likely binds to ATP-sensitive potassium channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Membrane depolarization stimulates calcium ion influx through voltage-sensitive calcium channels. This increase in intracellular calcium ion concentration, thus it induces the secretion of insulin.